Hansa Biopharma publishes 2023 Annual and Sustainability Reports
Company delivered significant progress across commercial and R&D priorities
Søren Tulstrup, President and CEO,
2023 highlights
Commercial and access progress were underpinned by expanded access in
Advancements in clinical development activities were marked by the conclusion of a long-term follow-up study of imlifidase in kidney transplantation (17-HMedIdeS-14) that confirmed sustained benefit up to five years, positive high level data from a phase 2 trial in Guillain-Barré Syndrome (GBS) (15-HMedIdeS-09), and first patient treated in a pivotal phase 3 trial in anti-glomerular basement membrane disease (anti-GBM) (GOODIDES-02) and in a new investigator-initiated phase 2 study in ANCA-associated vasculitis (ImlifidARDSe.01).
In its commitment to advance the science of immunomodulating therapies, Hansa moved into the clinical setting (NICE-01) with HNSA-5487, the lead candidate from its next generation of IgG-cleaving enzymes program (NiceR), sharing encouraging high-level results on safety and tolerability, pharmacokinetics and pharmacodynamics.
In the gene therapy space, Hansa remains focused on collaborating with leading gene therapy innovators to potentially enable more patients to access life-altering gene therapies. The Company's partnership with Sarepta Therapeutics has now moved to clinical stage with the initiation of the first clinical trial assessing imlifidase as a pre-treatment to SRP-9001 gene therapy in Duchenne Muscular Dystrophy (DMD). In 2023 Hansa also formed a partnership with Généthon, a leading gene therapy non-profit research organization, to evaluate imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome.
Hansa's journey towards a more sustainable business
At Hansa, sustainability is considered an important part of our overall business. Hansa's 2023 Sustainability Report highlights the Company's continued efforts in priority therapeutic areas, to ensure we are operating a transparent, ethical business with appropriate governance, while advancing a culture that is diverse, inclusive, and supportive of all employees.
Hansa uses an annual company-wide survey by
Read the Annual and Sustainability reports here
This is information that
Contacts for more information:
Klaus Sindahl, Head of Investor Relations
M: +46 (0) 709 298 269
E: klaus.sindahl@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
HansaBiopharma_AnnualReport_2023_ENG |
|
549300LLEO25ZJJ3NT91-2023-12-31-sv.zip |
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-publishes-2023-annual-and-sustainability-reports-302095574.html